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of 136 patients returned their bottles and completed a telephone
survey. At Month 3, 98.53% of patients reported via telephone
that they continually took the drug; 0.74% had temporary inter-
ruptions of the drug; 0.74% discontinued the drug early. At
Month 3, MEMS data for those patients reported 44.85% with
continuous administration, 39.71% with temporary interrup-
tions, 15.44% discontinued early. Kw at Month 3 was 0.036
(95% CI = -0.018, 0.091). At Month 6, 83.82% of patients
reported via telephone that they completed taking the drug;
15.44% were still taking the drug; 0.74% discontinued the drug
early. At Month 6, MEMS data for those patients reported
63.24% completed, 0.74% were still taking, 36.03% discontin-
ued early. Kw at Month 6 was 0.069 (95% CI = -0.005, 0.144).
CONCLUSION: Based on the kappa statistic, there was little
agreement between the patient-reported and electronic methods
of measuring compliance. Patients reported being much more
compliant with their medication regimen than was reported by
MEMS.
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OBJECTIVES: A previous study conducted by the authors indi-
cated that calcium channel blockers, ACE inhibitors, beta block-
ers and diuretics were the four most commonly used therapeutic
classes of antihypertensives in a commercial HMO population.
The objective of this study was to compare adherence between
these four classes of antihypertensives. METHODS: This study
was a retrospective pharmacy claims database analysis. All
members evaluated had a diagnosis of hypertension, received at
least two prescriptions for an antihypertensive drug, and were
continuously enrolled during the one-year study period. The
average medication possession ratio (MPR) was used as a
primary adherence indicator. An analysis of covariance was con-
ducted to determine if differences in the mean MPR existed based
on the antihypertensive therapeutic class. Previous research in
this population indicated that age, units per day of the drug,
number of concurrent medications and total days supply were
signiﬁcant predictors of adherence. These factors were for in this
analysis. RESULTS: The average MPR was evaluated for 1637
members meeting the inclusion criteria. The average age of the
members was 52.85 year and 53.63% were female. The mean
(S.D.) MPR for the therapeutic classes were: ACE inhibitors
0.8626 (0.2370), beta-blockers 0.8534 (0.2288), calcium
channel blockers 0.8770 (0.2078), diuretics 0.8291 (0.2705).
The MPR were signiﬁcantly higher in members on calcium
channel blockers versus diuretics (mean difference = 0.0524,
95% CI = 0.0140–0.0907, p < 0.005) and ACE inhibitors versus
diuretics (mean difference = 0.0473, 95% CI = 0.0139–0.0808,
p < 0.005). There were no signiﬁcant differences in adherence
between the other classes of antihypertensives. CONCLUSIONS:
After controlling for signiﬁcant predictors of adherence, the
MPR for members on calcium channel blockers and ACE
inhibitors were signiﬁcantly higher than for those patients on
diuretics. These results may have implications for the effective-
ness of different therapeutic classes of antihypertensives in blood
pressure control.
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OBJECTIVE: The objective of this study was to quantify the
clinical and economic effects of non-adherence with triple
therapy in treatment-naïve HIV patients. METHODS: A
Markov model was developed to project quality-adjusted life
expectancy and direct medical costs for HIV patients (mean age
= 37 years) on an initial regimen of highly active antiretroviral
therapy (HAART) with efavirenz, lamivudine and extended
release stavudine given once daily. Each month, patients faced a
risk of transition to AIDS that was a function of viral load, CD4
count, and adherence to drug therapy. Patients were assumed to
change to another triple-therapy regimen if their viral load was
≥ 400 copies/mL or if they transitioned to AIDS. After four reg-
imens, patients followed the natural history of the disease. We
compared clinical and economic outcomes for two adherence
scenarios: “clinical trial” (representing ideal utilization observed
in clinical trials) and “typical” (based on observational studies
in actual practice). Costs were derived from the HIV/AIDS Costs
and Services Utilization Survey and average wholesale drug
prices. Future costs and QALYs were discounted 3%. RESULTS:
Mean discounted quality-adjusted life expectancy was 8.6 and
10.0 QALYs under the typical and clinical trial adherence sce-
narios, respectively. Lifetime direct medical costs in the typical
and trial scenarios were $295,000 and $336,000, respectively.
Compared with typical adherence, clinical trial adherence con-
ferred an average gain of 1.4 QALYs at an incremental cost of
$29,000 per QALY gained. Up to $1650 per patient per year
could be spent on an intervention to improve adherence from
typical to trial levels, and the incremental cost-effectiveness of
doing so would remain below $50,000 per QALY gained. CON-
CLUSIONS: Typical adherence with HAART reduces quality-
adjusted life expectancy by 14% compared to adherence levels
in clinical trials. Programs to improve adherence appear to be a
highly cost-effective use of resources.
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OBJECTIVES: Information on the comparative effectiveness of
different antipsychotic medications in a naturalistic setting is
important for clinicians and other health care decision-makers.
However, in long-term naturalistic studies, patients may remain
on treatment, switch, augment, or even stop treatment at any
time and for different reasons—making statements about the
causal effects of treatments difﬁcult. The objective of this
research was to assess several analytic strategies for comparing
treatment effectiveness in the presence of switching. METHODS:
Using data from a recently completed 1-year, randomized, natu-
ralistic, anti-psychotic cost-effectiveness trial for schizophrenia,
three different analysis strategies were utilized to compare the
effectiveness of treatments on schizophrenia symptom severity
(measured by BPRS total score): intent-to-treat, sub-setting by
